Anavex Life Sciences Corp (AVXL)

[kund]

There are SEC rules for an officer of a company pumping a stock with false information.

That’s exactly what the commenter is pointing out—TGD continues to provide false information in every conference without facing any accountability. He’s emboldened because neither the SEC nor shareholders can take action, yet shareholders keep losing their hard-earned money due to his constant pumping with false information. He has been posting on LinkedIn for the past month, repeating the same information and then adding, "The following might be relevant in this context." What does that even mean? Instead of wasting time on LinkedIn, he should focus on getting the drug approved by the FDA. The FDA isn’t going to invite him to file an NDA—it’s his responsibility. And for a $4-5 million salary per year, he’s doing a lousy job.

The AD Phase 2a trial was completed in 2015, and the Phase 2b/3 trial started in 2018—meaning he took three years just to design another tiny trial. The trial itself took four years to complete, and then another 2.5 years to release junk data. In total, he has spent 10 years on the Phase 2b/3 trial.